Inlyta

Axitinib, the active ingredient in Inlyta, is a tyrosine kinase inhibitor classified as an antineoplastic agent and presented as 1 mg, 2 mg, and 5 mg oral tablets. It targets vascular endothelial growth factor receptors to inhibit angiogenesis and is indicated for the treatment of metastatic renal cell carcinoma in adult patients.

GNH USA supplies Inlyta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, adhering to EU quality standards and providing reliable logistics for clinical use.

Inlyta (axitinib) is used in cancers driven by vascular endothelial growth factor signaling, primarily metastatic renal cell carcinoma.

Metastatic renal cell carcinoma: improves